Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Oct 7;3(6):291.
doi: 10.1002/iju5.12228. eCollection 2020 Nov.

Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

Takeshi Yuasa  1
Affiliations
Editorial

Editorial comment from Dr Yuasa to Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma

Takeshi Yuasa. IJU Case Rep. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

References

    1. Tenold M, Ravi P, Kumar M et al Current approaches to the treatment of advanced or metastatic renal cell carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2020; 40: 1–10. - PubMed
    1. Escudier B, Porta C, Schmidinger M et al ESMO guidelines committee. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Ann. Oncol. 2019; 30: 706–20. - PubMed
    1. Dragomir A, Nazha S, Wood LA et al Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: the Canadian Kidney Cancer information system experience. Urol. Oncol. 2020; 38: 799‐e1. - PubMed
    1. Hagimoto H, Kashima S, Doi K et al Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. IJU Case Rep. 2020; 3: 287–90. - PMC - PubMed
    1. Ishihara H, Takagi T, Kondo T et al Nivolumab treatment beyond progression for metastatic renal cell carcinoma: new role of metastasectomy in the immune checkpoint inhibitor era? Int. J. Urol. 2020; 27: 691–2. - PubMed

Publication types